InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – VolitionRx (NYSE American: VNRX) Expands Fujifilm Vet Systems Agreement to Develop Nu.Q Vet Feline Cancer Test in Japan
November 17, 2026

InvestorNewsBreaks – VolitionRx (NYSE American: VNRX) Expands Fujifilm Vet Systems Agreement to Develop Nu.Q Vet Feline Cancer Test in Japan

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced the expansion of its supply agreement with Fujifilm Vet Systems Co. Ltd. in Japan to include the development and use of its Nu.Q Vet Feline Test. The agreement builds on the July 2024 launch of the Nu.Q Vet Canine Test in Japan, where growing veterinary demand prompted the introduction of an automated version earlier this year. The expansion follows research demonstrating high accuracy for a prototype feline assay in detecting lymphoma, the most common cancer in cats. Fujifilm plans to conduct an additional study with veterinary oncologists in Japan.

Volition said the expanded agreement presents a potential revenue opportunity in Japan, where the feline population approaches 9 million. The company is continuing product development of the blood-based feline cancer test, with plans to launch it on the Immunodiagnostic Systems (“IDS”) i10 automated analyzer platform. Volition aims to make cancer screening a routine component of annual veterinary wellness examinations, extending its existing canine testing technology to address the need for earlier cancer detection in cats.

To view the full press release, visit: https://ibn.fm/6fgSw

About Volition 

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Ellen Amonoo, Volition, [email protected]

For further information, visit the company’s website at https://volition.com/

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).